Beta catenin market

Beta Catenin Market, by Type (BBI-801, Exisulind, M-101, Nefopam Hydrochloride, and Others), by Application (Dermatology ,Oncology ,Genetic Disorder, and Others), and by Region (North America, Latin America, Europe, Asia-Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Request Free Sample

Sep 2022
CMI5258
156 Pages
Excel & Pdf
Pharmaceutical

Summary

Β-catenin is a multifunctional protein that is essential for preserving physiological homeostasis. A variety of illnesses, including cancer, are caused by its aberrantly high expression. The human equivalent of the drosophila armadillo gene is called β-catenin. It serves as an adapter protein for intracellular adhesion as well as a transcriptional co-regulator.

Global beta catenin market is estimated to be valued at US$ 2,492.0 million in 2022 and is expected to exhibit a CAGR of 9.6 % during the forecast period (2022-2030).

Figure 1.Global Beta Catenin Market Share (%) in Terms of Value, by Type, 2022

Rise in the incidence of genetic disorders is expected to drive growth of the beta catenin market.

Rise in the incidence of genetic disorders is expected to drive growth of the beta catenin market. For instance, according to data published on May 2022, by Centers for Disease Control and Prevention (CDC), Sickle Cell Disease (SCD) affects approximately 100,000 Americans every year.

Beta Catenin Market Report Coverage

Report Coverage	Details
Base Year:	2021	Market Size in 2022:	US$ 2,492.0 Mn
Historical Data for:	2017-2020	Forecast Period:	2022 to 2030
Forecast Period 2022 to 2030 CAGR:	9.6 %	2030 Value Projection:	US$ 5,201.5 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC Countries, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Type: BBI-801, Exisulind, M-101, Nefopam Hydrochloride, Others By Application: Dermatology, Oncology, Genetic Disorder, Others
Companies covered:	Boston Biomedical Inc, Dicerna Pharmaceuticals Inc., Marina Biotech Inc., Propanac Biopharma Inc, Warp Drive Bio Inc., prism pharma co ltd, , aileron therapeutics inc, MD2 Biosciences Inc, WntRx Pharmaceuticals Inc, Sapience Therapeutics Inc, and Venn Therapeutics LLC
Growth Drivers:	Increasing number of genetic disorders Increase in approval of gene therapies
Restraints & Challenges:	High cost involved in the treatment of cancer

Figure 2. Global Beta Catenin Market Share (%), By Region, 2022

Increase in approval of gene therapies drugs is expected to drive the market growth during the forecast period.

Increase in approval of gene therapies drugs is expected to drive the market growth during the forecast period. For instance, in May 2019, the U.S Food and Drug Administration (FDA) approved Zolgensma, for the treatment of pediatric patients less than two years of age with a specific type of spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.

Global Beta Catenin Market– Impact of Coronavirus (COVID-19) Pandemic

COVID-19 has created significant difficulties for the world economy in addition to placing a great deal of strain on the medical system. COVID-19 has created significant difficulties for the world economy in addition to placing a significant amount of strain on the medical system. Due to the effect on different diagnoses, therapies, and research and development that were all focused on working for COVID-19, the catenin beta market was impacted. Catenin beta demand was lower than the catenin beta market's revenue, which also decreased. the COVID-19 pandemic due to the catenin beta market's use in a number of medical fields, such as dermatology, oncology, and genetic disorders for the treatment of various diseases as well as in the development of a number of medications.

Global Beta Catenin Market: Restraint

The major factors that are expected to hinder growth of the global beta catenin market include high cost involved in the treatment of cancer. For instance, according to data published on April 2022, by National Cancer Institutewhich is the federal government's principal agency for cancer research and training, states that the average cost of medical care and drugs can cost up to US $42,000 in the year following a cancer diagnosis. Some treatments can exceed $1 million.

Key Players

Major players operating in the global beta catenin market include Boston Biomedical Inc, Dicerna Pharmaceuticals Inc., Marina Biotech Inc.,Propanac Biopharma Inc, Warp Drive Bio Inc.,prism pharma co ltd,aileron therapeutics inc, MD2 Biosciences Inc,WntRx Pharmaceuticals Inc, Sapience Therapeutics Inc, and Venn Therapeutics LLC.

Table of Content

Table of Contents

*Browse 27 market data tables and 31 figures on "Global Beta Catenin Market” - Forecast to 2030

Segmentation

Detailed Segmentation:

Global Beta Catenin Market, By Type:

BBI-801
Exisulind
M-101
Nefopam Hydrochloride
Others

Global Beta Catenin Market, By Application:
- Dermatology
- Oncology
- Genetic Disorder
- Others
Global Beta Catenin Market, By Region:
- North America
  - By Type
    - BBI-801
    - Exisulind
    - M-101
    - Nefopam Hydrochloride
    - Others
  - By Application
    - Dermatology
    - Oncology
    - Genetic Disorder
    - Others
  - By Country
    - U.S.
    - Canada
- Latin America
  - By Type
    - BBI-801
    - Exisulind
    - M-101
    - Nefopam Hydrochloride
    - Others
  - By Application
    - Dermatology
    - Oncology
    - Genetic Disorder
    - Others
  - By Country
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Europe
  - By Type
    - BBI-801
    - Exisulind
    - M-101
    - Nefopam Hydrochloride
    - Others
  - By Application
    - Dermatology
    - Oncology
    - Genetic Disorder
    - Others
  - By Country
    - Germany
    - U.K.
    - France
    - Italy
    - Spain
    - Russia
    - Rest of Europe
- Asia Pacific
  - By Type
    - BBI-801
    - Exisulind
    - M-101
    - Nefopam Hydrochloride
    - Others
  - By Application
    - Dermatology
    - Oncology
    - Genetic Disorder
    - Others
  - By Country
    - China
    - India
    - Japan
    - Australia
    - South Korea
    - ASEAN
    - Rest of Asia Pacific
- Middle East
  - By Type
    - BBI-801
    - Exisulind
    - M-101
    - Nefopam Hydrochloride
    - Others
  - By Application
    - Dermatology
    - Oncology
    - Genetic Disorder
    - Others
  - By Country
    - GCC
    - Israel
    - Rest of Middle East
- Africa
  - By Type
    - BBI-801
    - Exisulind
    - M-101
    - Nefopam Hydrochloride
    - Others
  - By Application
    - Dermatology
    - Oncology
    - Genetic Disorder
    - Others
  - By Country
    - South Africa
    - Central Africa
    - North Africa

- Frequently Asked Questions -

What is the current market size and compound annual growth rate (CAGR) of the global market during the forecast period (2022-2030)?

Global beta catenin market size is estimated to be valued at US$ 2,492.0 million in 2022 and is expected to exhibit a CAGR of 9.6 % between 2022 and 2030.

What are the major factors driving the market growth?

Factors such as increase in the number of genetic disorders & increase in approval of gene therapies are expected to drive the market growth over the forecast period.

Which is the leading region segment in the market?

North America is expected to hold a major market share during the forecast period.

What are the key factors hampering growth of the market?

The major factor hampering growth of the market is high cost involved in the treatment of cancer.

Which are the major players operating in market?

Major players operating in the market include Boston Biomedical Inc, Dicerna Pharmaceuticals Inc., Marina Biotech Inc., Propanac Biopharma Inc, Warp Drive Bio Inc., prism pharma co ltd, , aileron therapeutics inc, MD2 Biosciences Inc, WntRx Pharmaceuticals Inc, Sapience Therapeutics Inc, and Venn Therapeutics LLC.